Daily Stock Analysis, ARNA, Arena Pharmaceuticals Inc, priceseries

Arena Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
1.46
Close
1.47
High
1.47
Low
1.45
Previous Close
1.45
Daily Price Gain
0.02
YTD High
1.70
YTD High Date
Mar 15, 2017
YTD Low
1.34
YTD Low Date
Jan 20, 2017
YTD Price Change
-0.00
YTD Gain
-0.34%
52 Week High
2.16
52 Week High Date
Jun 9, 2016
52 Week Low
1.34
52 Week Low Date
Jan 20, 2017
52 Week Price Change
-0.36
52 Week Gain
-19.95%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 17. 2016
1.53
Apr 8. 2016
1.88
15 Trading Days
22.55%
Link
LONG
May 20. 2016
1.57
Jun 15. 2016
1.95
17 Trading Days
24.43%
Link
Company Information
Stock Symbol
ARNA
Exchange
NasdaqGS
Company URL
http://www.arenapharm.com
Company Phone
858-453-7200
CEO
Amit D. Munshi
Headquarters
California
Business Address
6154 NANCY RIDGE DRIVE, SAN DIEGO, CA 92121
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001080709
About

Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors to address unmet medical needs in the United States and South Korea.

Description

Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors to address unmet medical needs in the United States and South Korea. The company offers BELVIQ, a drug used to treat chronic weight management in adults. It is also developing a portfolio of programs in various therapeutic areas, including cardiovascular, central nervous system, and metabolic diseases. Its products under development include APD334, a modulator of the sphingosine 1-phosphate subtype 1 receptor for the treatment of a various autoimmune diseases, which is in Phase II clinical trials; and Ralinepag that is in Phase II clinical trials for the treatment of pulmonary arterial hypertension. The company's products under development also comprise APD371, an agonist of the cannabinoid-2 receptor that is in Phase I clinical trials for the treatment of pain; Nelotanserin, which is in Phase II clinical trials for the treatment of dementia-associated psychosis; Temanogrel, which is in Phase I clinical trials for thrombotic diseases; and Undisclosed Orphan GPCR that is in pre-clinical development for central nervous system indications. In addition, it manufactures drug products under a toll manufacturing agreement for Siegfried AG. Arena Pharmaceuticals, Inc. has collaboration with Boehringer Ingelheim International GmbH. The company was founded in 1997 and is based in San Diego, California.